Tokyo, Japan

Daisuke Kataoka

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Daisuke Kataoka: Innovator in Medicinal Composition

Introduction

Daisuke Kataoka is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the treatment of secondary hyperparathyroidism. His innovative approach has led to the development of a unique medicinal composition that addresses a critical health issue for patients undergoing maintenance dialysis.

Latest Patents

Kataoka holds a patent for a medicinal composition aimed at preventing or treating secondary hyperparathyroidism under maintenance dialysis. This composition includes 3-{[(2S)-2-amino-2-carboxyethyl]carbamoylamino}-5-chloro-4-methylbenzenesulfonic acid or a pharmaceutically acceptable salt thereof. The invention is designed to be administered through a predefined route and dosage, providing a prophylactic or therapeutic agent that exhibits reduced side effects and minimal accumulation in the body. This innovative medicinal agent allows for easier management of administration and offers a higher safety profile compared to conventional treatments.

Career Highlights

Daisuke Kataoka has established himself as a key figure in the pharmaceutical industry. His work at Ea Pharma Co., Ltd. has been instrumental in advancing therapeutic options for patients with specific medical needs. His dedication to research and development has resulted in impactful innovations that enhance patient care.

Collaborations

Kataoka has collaborated with notable colleagues, including Kazuo Kuyama and Kenji Asano. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further driving innovation in their field.

Conclusion

Daisuke Kataoka's contributions to medicinal chemistry exemplify the importance of innovation in healthcare. His patented composition for treating secondary hyperparathyroidism represents a significant advancement in patient treatment options. Through his work, he continues to make a positive impact on the lives of patients undergoing maintenance dialysis.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…